Benacerraf B R, Neuberg D, Bromley B, Frigoletto F D
Department of Obstetrics & Gynecology, Brigham & Women's Hospital, Boston, Massachusetts.
J Ultrasound Med. 1992 Sep;11(9):449-58. doi: 10.7863/jum.1992.11.9.449.
Current indications for cytogenetic evaluation leave the majority of Down syndrome fetuses undetected. Using advanced maternal age and low maternal serum alpha-fetoprotein (AFP) levels as criteria, only 40% of fetuses with Down syndrome (trisomy 21) are identified (positive predictive value, 0.4% to 1%). We evaluate the sonographically detectable physical features of second trimester fetuses to determine whether these features are more sensitive and specific than maternal age for detecting fetuses with abnormal karyotypes. From March 1, 1990, to September 1, 1991, more than 5,000 fetuses between 14 and 20 weeks of development were referred for genetic amniocentesis because of advanced maternal age or abnormal AFP levels. Forty-three of these 5,000 fetuses were later found to have autosomal trisomies by karyotype (32 with trisomy 21, nine with trisomy 18, and two with trisomy 13). A sample of 588 consecutive normal fetuses from the total of more than 5,000 amniocenteses performed during this period of time was used as our control group for statistical analysis. The sonographic features of these 588 normal second trimester fetuses and the 43 trisomic fetuses recorded prospectively prior to knowledge of the karyotype were evaluated statistically. The femur and humerus lengths, nuchal fold, renal pelvic dimension, and major structural defects were compared in the normal and trisomic fetuses. On the basis of our results, a weighted sonographic score was developed to optimize the detection of fetuses at risk for aneuploidy. Using our previously published formulas and criteria for a short femur and humerus, 17/32 (53%) fetuses with Down syndrome and 23/588 (3.9%) of the normal fetuses were identified. Twenty two of 32 Down syndrome fetuses (69%) and 2/588 (0.34%) of normals had a nuchal fold > or = 6 mm, and 11 of 32 Down syndrome fetuses and all those with trisomies 18 and 13 had a major anomaly detected sonographically. The following scoring system was developed for the detection of aneuploidy: nuchal fold = 2, major structural defect = 2, and short femur, short humerus, and pyelectasis = 1 each. Selecting fetuses with a score of > or = 2 would identify 26/32 (81%) Down syndrome fetuses, and 9/9 (100%) and 2/2 (100%) fetuses with trisomies 18 and 13 respectively, but only 26/588 (4.4%) of the normal fetuses. Using the sonographic score of 2 results in a positive predictive value for a 1/250 risk group of 6.87% for identifying Down syndrome fetuses and 7.25% for all three trisomies.(ABSTRACT TRUNCATED AT 400 WORDS)
目前细胞遗传学评估的指征使得大多数唐氏综合征胎儿未被检测出来。以高龄产妇和低母体血清甲胎蛋白(AFP)水平作为标准,仅有40%的唐氏综合征(21三体)胎儿能被识别出来(阳性预测值为0.4%至1%)。我们评估孕中期胎儿超声可检测到的身体特征,以确定这些特征对于检测染色体核型异常胎儿是否比产妇年龄更敏感、更具特异性。从1990年3月1日至1991年9月1日,超过5000名孕14至20周的胎儿因产妇年龄偏大或AFP水平异常而被转诊进行遗传羊膜腔穿刺术。这5000名胎儿中,有43名后来经染色体核型分析发现患有常染色体三体(32例为21三体,9例为18三体,2例为13三体)。在此期间进行的5000多次羊膜腔穿刺术中连续选取的588例正常胎儿样本用作我们的统计分析对照组。对这588例正常孕中期胎儿以及43例三体胎儿在得知核型之前前瞻性记录的超声特征进行了统计评估。比较了正常胎儿和三体胎儿的股骨和肱骨长度、颈部褶皱、肾盂大小以及主要结构缺陷。根据我们的结果,制定了一个加权超声评分,以优化对非整倍体风险胎儿的检测。根据我们之前发表的关于股骨和肱骨短小的公式及标准,32例唐氏综合征胎儿中有17例(53%)以及588例正常胎儿中有23例(3.9%)被识别出来。32例唐氏综合征胎儿中有22例(69%)以及588例正常胎儿中有2例(0.34%)颈部褶皱≥6毫米,32例唐氏综合征胎儿中有11例以及所有18三体和13三体胎儿经超声检测出有主要异常。为检测非整倍体制定了以下评分系统:颈部褶皱=2分,主要结构缺陷=2分,股骨短小、肱骨短小以及肾盂扩张各=1分。选择评分≥2分的胎儿可识别出32例唐氏综合征胎儿中的26例(81%)、18三体胎儿中的9例(100%)以及13三体胎儿中的2例(100%),但仅能识别出正常胎儿中的26例(4.4%)。对于1/250风险组,使用超声评分2分识别唐氏综合征胎儿的阳性预测值为6.87%,识别所有三种三体的阳性预测值为7.25%。(摘要截选至400字)